BACKGROUND: A growing body of evidence suggests that earlier diagnosis and treatment of diabetes may be beneficial; however, definitive evidence is lacking. AIM: To evaluate the effectiveness of an intensified multifactorial treatment on cardiovascular risk factors in patients with screen-detected type 2 diabetes. DESIGN OF STUDY: Randomised controlled trial. SETTING: Seventy-nine general practices in the southwestern region of the Netherlands. METHOD: In this randomised trial, patients diagnosed with diabetes by screen-detection were assigned to intensified (n = 255) or routine treatment (n = 243), and followed over 1 year. Intensified treatment consisted of pharmacological treatment combined with lifestyle education to achieve haemoglobin A1c (HbA1c) <7.0%, blood pressure <135/85 mmHg, and cholesterol <5.0 mmol/l (4.5 mmol/l if cardiovascular disease was present). Health-related quality of life (HRQoL) was assessed using the Short Form (SF)-36. Analyses were performed using generalised estimating equations models. RESULTS: Changes in body mass index were 0.2 (routine care) versus -1.4 kg/m(2) (intensified treatment), P<0.001; systolic blood pressure -19 versus -33 mmHg, P<0.001; diastolic blood pressure -7 versus -12 mmHg, P<0.001; HbA1c -0.9% versus -1.1%, P = 0.03; cholesterol -0.5 versus -1.2 mmol/l, P<0.001; high-density lipoprotein cholesterol 0.1 versus 0.1 mmol/l, P = 0.26; low-density lipoprotein cholesterol -0.5 versus -1.0 mmol/l, P<0.001; triglycerides -0.3 versus -0.4 mmol/l, P = 0.71. No difference in HRQoL between the two groups was reported. CONCLUSION:Intensified multifactorial treatment of patients with screen-detected diabetes in general practice reduces cardiovascular risk factor levels significantly without worsening HRQoL.
RCT Entities:
BACKGROUND: A growing body of evidence suggests that earlier diagnosis and treatment of diabetes may be beneficial; however, definitive evidence is lacking. AIM: To evaluate the effectiveness of an intensified multifactorial treatment on cardiovascular risk factors in patients with screen-detected type 2 diabetes. DESIGN OF STUDY: Randomised controlled trial. SETTING: Seventy-nine general practices in the southwestern region of the Netherlands. METHOD: In this randomised trial, patients diagnosed with diabetes by screen-detection were assigned to intensified (n = 255) or routine treatment (n = 243), and followed over 1 year. Intensified treatment consisted of pharmacological treatment combined with lifestyle education to achieve haemoglobin A1c (HbA1c) <7.0%, blood pressure <135/85 mmHg, and cholesterol <5.0 mmol/l (4.5 mmol/l if cardiovascular disease was present). Health-related quality of life (HRQoL) was assessed using the Short Form (SF)-36. Analyses were performed using generalised estimating equations models. RESULTS: Changes in body mass index were 0.2 (routine care) versus -1.4 kg/m(2) (intensified treatment), P<0.001; systolic blood pressure -19 versus -33 mmHg, P<0.001; diastolic blood pressure -7 versus -12 mmHg, P<0.001; HbA1c -0.9% versus -1.1%, P = 0.03; cholesterol -0.5 versus -1.2 mmol/l, P<0.001; high-density lipoprotein cholesterol 0.1 versus 0.1 mmol/l, P = 0.26; low-density lipoprotein cholesterol -0.5 versus -1.0 mmol/l, P<0.001; triglycerides -0.3 versus -0.4 mmol/l, P = 0.71. No difference in HRQoL between the two groups was reported. CONCLUSION: Intensified multifactorial treatment of patients with screen-detected diabetes in general practice reduces cardiovascular risk factor levels significantly without worsening HRQoL.
Authors: Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen Journal: N Engl J Med Date: 2003-01-30 Impact factor: 91.245
Authors: Antonia F H Smelt; Gerda M van der Weele; Jeanet W Blom; Jacobijn Gussekloo; Willem J J Assendelft Journal: Br J Gen Pract Date: 2010-07 Impact factor: 5.386
Authors: Morten Charles; Rebecca K Simmons; Kate M Williams; Gojka Roglic; Stephen J Sharp; Ann-Louise Kinmonth; Nicholas J Wareham; Simon J Griffin Journal: Br J Gen Pract Date: 2012-06 Impact factor: 5.386
Authors: Maria I Creatore; Gillian L Booth; Douglas G Manuel; Rahim Moineddin; Richard H Glazier Journal: Diabetes Care Date: 2012-02-22 Impact factor: 19.112
Authors: R K Simmons; S J Sharp; A Sandbæk; K Borch-Johnsen; M J Davies; K Khunti; T Lauritzen; G E H M Rutten; M van den Donk; N J Wareham; S J Griffin Journal: Diabet Med Date: 2012-11 Impact factor: 4.359